



July 24, 2026

Hycor Biomedical
Aashrey Kaul
Regulatory Affairs and Quality Assurance Manager
7272 Chapman Ave.
Garden Grove, California 92841

Re: K261027

Trade/Device Name: NOVEOS Specific IgE (sIgE)
Capture Reagent F014, Soybean (Glycine max)
Capture Reagent F017, Hazelnut (Corylus avellana)
Capture Reagent F352, Ara h 8 PR-10, Peanut
Capture Reagent F423, Ara h 2, Peanut
Capture Reagent F447, Ara h 6, Peanut
Regulation Number: 21 CFR 866.5750
Regulation Name: Radioallergosorbent (RAST) immunological test system
Regulatory Class: Class II
Product Code: DHB
Dated: June 25, 2026
Received: June 26, 2026

Dear Aashrey Kaul:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of

Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system>.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn

(<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Ying Mao -S

Ying Mao, PhD
Branch Chief
Division of Immunology and Hematology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K261027

Device Name

NOVEOS Specific IgE (sIgE);

Capture Reagent F014, Soybean (Glycine max);

Capture Reagent F017, Hazelnut (Corylus avellana);

Capture Reagent F352, Ara h 8 PR-10, Peanut;

Capture Reagent F423, Ara h 2, Peanut;

Capture Reagent F447, Ara h 6, Peanut

Indications for Use (Describe)

The NOVEOS™ Specific IgE Assay is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum. NOVEOS Specific IgE Assay is to be used with the NOVEOS Immunoassay Analyzer. It is intended for use as an in vitro diagnostic aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings and is to be used in clinical laboratories.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



510(k) Summary

NOVEOS® Specific IgE

This 510(k) summary is prepared in accordance with the requirements of 21 CFR Part 807.92.

Date of Preparation: 25th June 2026

Manufacturer: Hycor Biomedical, LLC
7272 Chapman Avenue
Garden Grove, CA 92841

Contact Person: Aashrey Kaul
Regulatory Affairs and Quality Assurance Manager
7272 Chapman Ave
Garden Grove, CA 92841
(714) 933-3067
akaul@hycorbiomedical.com

Device Name:

NOVEOS® Specific IgE (sIgE)
Capture Reagent F014, Soybean (*Glycine max*);
Capture Reagent F017, Hazelnut (*Corylus avellana*);
Capture Reagent F352, Ara h 8 PR-10, Peanut;
Capture Reagent F423, Ara h 2, Peanut;
Capture Reagent F447, Ara h 6, Peanut

Classification

NOVEOS® Specific IgE (sIgE)
Product Code: DHB
Class: II
CFR § 866.5750

Substantial Equivalence to: K051218

ImmunoCAP Specific IgE

ImmunoCAP Allergens f14, f17, f352, f423, and f447

Indications for Use/ Intended Use

The NOVEOS™ Specific IgE assay is an *in vitro* quantitative assay for the measurement of allergen specific IgE in human serum. NOVEOS Specific IgE assay is to be used with the NOVEOS Immunoassay Analyzer. It is intended for use as an *in vitro* diagnostic aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings and is to be used in clinical laboratories.

General Description

Reagents

The IgE common reagents include: Diluent A, Conjugate IgE, Substrate A, Substrate B, and Fluo Beads™. Other required and recommended reagents include the allergen specific Capture Reagent, IgE Calibrator Set (6 levels (kU/L) - Cal 0.07 IgE, Cal 0.35 IgE, Cal 0.70 IgE, Cal 3.5 IgE, Cal 17.5 IgE, Cal 100 IgE), Calibrator Antibody IgE, Probe Wash Pack, Wash Buffer Concentrate, Cuvette Wash Pack, IgE Negative Control Pack, and IgE Positive Control Pack.

Assay Principle

The NOVEOS Specific IgE assay is an immunometric, chemiluminescent procedure for the quantitative determination of IgE of known specificity in human serum samples. It employs fluorescent labelled magnetic, streptavidin coated microparticles which are incubated with a biotinylated allergenic capture reagent, patient sample and monoclonal anti-human IgE antibody: horseradish peroxidase conjugate. If present in the sample, IgE binds to the biotinylated allergen captured to the streptavidin-coated microparticles to form a complex. After a final wash, the resulting complex is incubated with the enzyme substrate and a chemiluminescent signal is generated, the magnitude of which is proportional to the concentration of IgE in the patient sample.

The concentration of allergen-specific IgE is determined from a standard curve, which is traceable to the World Health Organization (WHO) reference reagent serum Immunoglobulin E (IgE) 11/234.

Device Comparison

NOVEOS Specific IgE assay on the NOVEOS Immunoassay Analyzer is comparable to ImmunoCAP Specific IgE on the Phadia 100 or 250 Analyzer. Both are automated immunoassay systems that process all assay steps and automatically generate results. See the table on the next page for a summary comparison of the two systems.

Similarities and Differences		
General Device Characteristic	NOVEOS Specific IgE	ImmunoCAP Specific IgE
Intended Use	The NOVEOS Specific IgE assay is an <i>in vitro</i> quantitative assay for the measurement of allergen specific IgE in human serum. NOVEOS Specific IgE assay is to be used with the NOVEOS Immunoassay Analyzer. It is intended for use as an <i>in vitro</i> diagnostic aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings and is to be used in clinical laboratories.	ImmunoCAP Specific IgE is an <i>in vitro</i> quantitative assay for the measurement of allergen specific IgE in human serum or plasma (EDTA or Na-Heparin). ImmunoCAP Specific IgE is to be used with instruments Phadia 100, Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000. It is intended for <i>in vitro</i> diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories.
Specimen Type	Serum	Serum or plasma (EDTA, Na Heparin)
Sample Volume	4 µL	40 µL
Assay Type	Quantitative	Same
Detection Antibody	Horseradish peroxidase conjugated mouse anti-human IgE monoclonal antibody	β-Galactosidase-anti-human IgE (mouse monoclonal antibody)
Detection Limit	<u>F014, Soybean:</u> LoB: 0.07 kU/L LoD: 0.09 kU/L LoQ: 0.10 kU/L <u>F017, Hazelnut:</u> LoB: 0.07 kU/L LoD: 0.08 kU/L LoQ: 0.10 kU/L <u>F352, Ara h 8 PR-10, Peanut:</u> LoB: 0.07 kU/L LoD: 0.08 kU/L	LoB: 0.001 kU/L LoD: 0.02 kU/L LoQ: 0.10 kU/L

	LoQ: 0.10 kU/L <u>F423, Ara h 2, Peanut:</u> LoB: 0.07 kU/L LoD: 0.09 kU/L LoQ: 0.10 kU/L <u>F447, Ara h 6, Peanut:</u> LoB: 0.07 kU/L LoD: 0.08 kU/L LoQ: 0.10 kU/L	
Laboratory Setting	Clinical Laboratory	Same
Assay Principles	Fluorescence adjusted, immunometric, chemiluminescent assay	Fluoroenzyme-immunoassay
Solid Phase	Magnetic microparticles	Cellulose derivative
Calibrator Traceability	World Health Organization (WHO) reference reagent serum Immunoglobulin E (IgE) 11/234	Same
Calibration Method	Heterologous interpolation based on Total IgE calibration curve	Same
Stored Calibration Curve	Yes, up to 28 days	Same
Number of Calibrators	Six	Same
Calibrator Levels	Six levels at 0.07, 0.35, 0.7, 3.5, 17.5 and 100 kU/L	Six levels at 0, 0.35, 0.7, 3.5, 17.5 and 100 kU/L
Assay Range	<u>F014, Soybean:</u> 0.10 – 100 kU/L <u>F017, Hazelnut:</u> 0.10 – 100 kU/L <u>F352, Ara h 8 PR-10, Peanut:</u> 0.10 – 100 kU/L <u>F423, Ara h 2, Peanut:</u> 0.10 – 99 kU/L	Same

	<u>F447, Ara h 6, Peanut:</u> 0.10 – 100 kU/L	
Reaction Temperature	37°C	Same
Instrument(s)	NOVEOS Immunoassay Analyzer	Phadia 100, Phadia 250/1000/2500/5000
Time to First Result	1 hour 45 minutes	1 hour 45 minutes to 2 hour 30 minutes depending on model

Clinical Performance

A clinical study that compares NOVEOS sIgE allergen results to the allergic status of 170 to 186 patients was performed to support the diagnostic performance of the NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut). A total of 39 to 56 samples with allergic status (atopic) was confirmed by physician diagnosis, and the other 126 to 132 samples were deemed negative (non-atopic) by ImmunoCAP testing (result <0.35 kU/L).

Results are expressed as positive when a sample has an sIgE value greater than or equal to 0.35 kU/L, and negative when a sample has an sIgE value is less than 0.35 kU/L. Clinical sensitivity and specificity for each allergen under evaluation are summarized in the following table:

NOVEOS sIgE Allergens		Clinical Diagnosis		
		Atopic	Non-Atopic	Total
F014, Soybean	Positive	35	0	35
	Negative	4	131	135
	Total	39	131	170
	Clinical sensitivity: 89.7% (95% CI 76.4% to 95.9%) Clinical specificity: 100.0% (95% CI 97.2% to 100.0%)			
F017, Hazelnut	Positive	47	2	49
	Negative	3	124	127
	Total	50	126	176
	Clinical sensitivity: 94.0% (95% CI 83.8% to 97.9%) Clinical specificity: 98.4% (95% CI 94.4% to 99.6%)			
F352, Ara h 8, Peanut	Positive	18	0	18
	Negative	36	132	168
	Total	54	132	186
	Clinical sensitivity: 33.3% (95% CI 22.2% to 46.6%) Clinical specificity: 100.0% (95% CI 97.2% to 100.0%)			
F423, Ara h 2, Peanut	Positive	42	0	42
	Negative	14	129	143
	Total	56	129	185
	Clinical sensitivity: 75.0% (95% CI 62.3% to 84.5%) Clinical specificity: 100.0% (95% CI 97.1% to 100.0%)			
F447, Ara h 6, Peanut	Positive	40	0	40
	Negative	16	126	142
	Total	56	126	182
	Clinical sensitivity: 71.4% (95% CI 58.5% to 81.6%) Clinical specificity: 100.0% (95% CI 97.0% to 100.0%)			

The following literature was published that supports the observed sensitivity of the NOVEOS sIgE assay F352, F423, and F447 allergens.

NOVEOS sIgE assay	Literature Citation(s)	Prevalence	Reported Performance
F352, Ara h 8, Peanut Sensitivity: 33.3% Specificity: 100.0%	Warren C., et al. J Allergy Clin Immunol. 2021;147(6):2263-2270.e5 (Results, Pages 3-4)	1.3% - 2.9% of US adults have a reported peanut allergy	not reported
	Calamelli E., et al. BioMed Research International. 2013, Article ID 170452, 5 pages (Table 1)	See reported sensitivity	Among children sensitized to peanut, only 35% had IgE reactivity to Ara h 8.
	Vereda A., et al. J Allergy Clin Immunol. 2011;127:603-7. (Table II)	See reported sensitivity	Among patients with peanut allergy, only 25% had IgE reactivity to Ara h 8.
F423, Ara h 2, Peanut Sensitivity: 75.0% Specificity: 100.0%	Warren C., et al. J Allergy Clin Immunol. 2021;147(6):2263-2270.e5 (Results, Pages 3-4)	1.3% - 2.9% of US adults have a reported peanut allergy	not reported
	Calamelli E., et al. BioMed Research International. 2013, Article ID 170452, 5 pages (Table 1)	See reported sensitivity	Among children sensitized to peanut, only 27% had IgE reactivity to Ara h 2.
	Vereda A., et al. J Allergy Clin Immunol. 2011;127:603-7. (Table II)	See reported sensitivity	Among patients with peanut allergy, only 64% had IgE reactivity to Ara h 2.
F447, Ara h 6, Peanut Sensitivity: 71.4% Specificity: 100.0%	Warren C., et al. J Allergy Clin Immunol. 2021;147(6):2263-2270.e5 (Results, Pages 3-4)	1.3% - 2.9% of US adults have a reported peanut allergy	not reported
	Kaur N., et al. J Allergy Clin Immunol Pract. 2021;9(1):245-53. (Table II)	See reported sensitivity	Among children referred for peanut OFC, 37% had IgE reactivity to Ara h 6. Among children found to be allergic to peanut by OFC, 75% had IgE reactivity to Ara h 6.

Precision/Reproducibility

Repeatability and within-laboratory precision of NOVEOS sIgE allergens were determined in accordance with CLSI guideline EP05-A3: *Evaluation of Precision of Quantitative Measurement*

Procedures – 3rd Edition and CLSI guideline EP15-A3: *User Verification of Precision and Estimation of Bias – 3rd Edition*. A panel of four to five samples (one to two negative and two to three positive patient samples) was assayed in replicates of two to five for one to two runs per day, over 20 to 21 days, on one to two NOVEOS Immunoassay Analyzers for a total of 80 to 92 replicates per sample. One lot of NOVEOS sIgE allergens was used for testing each sample.

The SD and % CV of the within- run, between-run, between-day, and total imprecision were calculated for each sample and results are summarized in the following table:

Sample	N	Mean (kU/L)	Within-Run (Repeatability)		Between-Run		Between-Day		Total	
			SD	CV	SD	CV	SD	CV	SD	CV
NOVEOS F014, Soybean										
1	80	0.16	0.01	6.7%	0.01	7.3%	0.01	5.0%	0.02	11.1%
2	82*	0.27	0.02	7.7%	0.01	3.3%	0.01	3.7%	0.02	9.1%
3	80	4.06	0.13	3.2%	0.11	2.7%	0.10	2.5%	0.20	4.8%
4	80	92.69	3.83	4.1%	5.51	5.9%	3.54	3.8%	7.59	8.2%
*Sample 2 had two outliers removed on Day 12 and one additional day (2 runs x 2 reps) was added										
NOVEOS F017, Hazelnut										
1	80	0.23	0.01	4.5%	0.01	4.4%	0.01	5.2%	0.02	8.2%
2	80	0.31	0.01	3.0%	0.03	10.3%	0.01	3.6%	0.04	11.3%
3	80	1.37	0.04	2.8%	0.05	3.9%	0.08	6.1%	0.11	7.8%
4	80	5.48	0.17	3.0%	0.27	5.0%	0.35	6.4%	0.47	8.6%
5	82*	88.97	7.35	8.3%	5.64	6.3%	0.00	0.0%	9.26	10.4%
*An extra day was tested to maintain the required 80 replicate minimum due to dropped replicates during testing										
NOVEOS F352, Ara h 8 PR-10, Peanut										
1	80	0.17	0.01	5.4%	0.00	2.7%	0.02	10.5%	0.02	12.1%
2	80	0.27	0.02	5.8%	0.01	4.7%	0.02	5.9%	0.03	9.5%
3	80	1.60	0.07	4.4%	0.01	0.9%	0.07	4.2%	0.10	6.2%
4	80	6.45	0.19	2.9%	0.13	2.0%	0.21	3.2%	0.31	4.7%
5	92*	81.42	6.32	7.8%	5.25	6.4%	2.23	2.7%	8.52	10.5%
*Sample 5 was tested with 5 replicates/1st run x 2 replicates/2nd run x 4 days and 2 replicates x 2 runs x 16 days										
NOVEOS F423, Ara h 2, Peanut										
1	80	0.14	0.01	9.9%	0.01	5.7%	0.01	6.0%	0.02	12.9%
2	80	0.32	0.03	8.0%	0.00	0.0%	0.00	0.0%	0.03	8.0%
3	80	2.75	0.15	5.5%	0.06	2.0%	0.11	4.0%	0.19	7.1%
4	80	77.35	4.15	5.4%	3.29	4.3%	2.37	3.1%	5.80	7.5%
NOVEOS F447, Ara h 6, Peanut										
1	80	0.19	0.01	6.2%	0.01	4.7%	0.01	3.5%	0.02	8.5%
2	89*	0.50	0.02	4.0%	0.02	4.2%	0.04	8.1%	0.05	10.0%

Sample	N	Mean (kU/L)	Within-Run (Repeatability)		Between-Run		Between-Day		Total	
			SD	CV	SD	CV	SD	CV	SD	CV
3	83**	4.49	0.34	7.6%	0.00	0.0%	0.14	3.2%	0.37	8.2%
4	80	76.23	5.03	6.6%	3.84	5.0%	3.89	5.1%	7.43	9.7%

*Sample 2 was tested with 5 replicates/1st run x 2 replicates/2nd run x 3 days and 2 replicates x 2 runs x 17 days
 **Sample 3 had one outlier removed on Day 19 and one additional day (2 runs x 2 reps) was added

Lot-to-lot imprecision

Lot-to-lot imprecision was evaluated using a panel of four to six serum samples tested with three different lots of each NOVEOS sIgE allergen. For NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) the samples were tested in replicates of five for one run per day, over 5 to 6 days, for a total of 75 to 79 replicates per sample. The results are summarized in the following table:

Sample	N	Mean (kU/L)	Within-Run (Repeatability)		Between-Day		Between-Lot		Total	
			SD	CV	SD	CV	SD	CV	SD	CV
NOVEOS F014, Soybean										
1	75	0.14	0.02	11.8%	0.01	10.4%	0.00	0.0%	0.02	15.7%
2	75	0.46	0.02	5.3%	0.01	3.0%	0.00	0.6%	0.03	6.2%
3	75	1.35	0.04	2.8%	0.05	3.4%	0.02	1.6%	0.06	4.7%
4	75	4.08	0.16	3.9%	0.11	2.7%	0.00	0.0%	0.19	4.7%
5	75	72.06	2.94	4.1%	2.16	3.0%	0.00	0.0%	3.65	5.1%
NOVEOS F017, Hazelnut										
1	75	0.15	0.01	8.7%	0.02	11.1%	0.00	0.0%	0.02	14.1%
2	75	0.46	0.02	5.2%	0.04	8.4%	0.00	0.0%	0.05	9.9%
3	75	1.49	0.06	3.8%	0.10	6.8%	0.00	0.0%	0.12	7.8%
4	75	6.04	0.30	4.9%	0.43	7.1%	0.18	2.9%	0.55	9.1%
5	75	60.28	2.66	4.4%	2.30	3.8%	0.00	0.0%	3.52	5.8%
6	79*	88.21	3.71	4.2%	5.92	6.7%	0.00	0.0%	6.99	7.9%
*Sample 6 had one outlier removed on Day 5 and one additional day (1 run x 5 reps) was added										
NOVEOS F352, Ara h 8 PR, Peanut										
1	75	0.18	0.01	6.0%	0.01	4.6%	0.01	2.9%	0.01	8.1%
2	75	0.31	0.02	5.1%	0.02	4.9%	0.01	4.3%	0.03	8.3%
3	75	0.56	0.04	6.5%	0.00	0.0%	0.04	7.9%	0.06	10.2%
4	75	1.51	0.05	3.5%	0.02	1.4%	0.04	2.7%	0.07	4.6%
5	75	5.93	0.21	3.6%	0.08	1.4%	0.07	1.1%	0.24	4.0%
6	75	78.85	4.84	6.1%	4.06	5.2%	0.00	0.0%	6.32	8.0%

Sample	N	Mean (kU/L)	Within-Run (Repeatability)		Between-Day		Between-Lot		Total	
			SD	CV	SD	CV	SD	CV	SD	CV
NOVEOS F423, Ara h 2, Peanut										
1	75	0.18	0.01	5.4%	0.01	3.2%	0.00	0.0%	0.01	6.2%
2	75	0.27	0.02	5.8%	0.01	4.3%	0.00	0.0%	0.02	7.2%
3	75	0.52	0.02	3.6%	0.03	5.5%	0.00	0.0%	0.03	6.6%
4	75	1.15	0.05	4.5%	0.06	5.5%	0.00	0.0%	0.08	7.1%
5	75	93.56	3.13	3.3%	4.00	4.3%	0.00	0.0%	5.07	5.4%
NOVEOS F447, Ara h 6, Peanut										
1	79*	0.20	0.01	5.5%	0.01	5.9%	0.00	0.7%	0.02	8.1%
2	75	0.47	0.02	4.1%	0.03	5.5%	0.01	1.7%	0.03	7.1%
3	75	9.98	0.40	4.0%	0.56	5.6%	0.00	0.0%	0.69	6.9%
4	75	75.92	3.98	5.2%	2.64	3.5%	0.00	0.0%	4.78	6.3%
*Sample 1 had one outlier removed on Day 5 and one additional day (1 run x 5 reps) was added										

Linearity

Linearity of NOVEOS sIgE allergens was evaluated in accordance with CLSI guideline I/LA20-3rd Edition, *Analytical Performance Characteristics, Quality Assurance, and Clinical Utility of Immunological Assays for Human Immunoglobulin E Antibodies of Defined Allergen Specificities*. Three sets of linearity dilution panels consisting of three neat positive human serum samples (low, mid, and high) were used for testing. One negative sample below the assay detection limit was used as the diluent. Each sample was serially diluted to create the full dilution panel. Testing was performed using one lot of each NOVEOS sIgE allergen. The linear regression statistics calculated using the weighted least squares with intercept analysis per CLSI guideline EP06-2nd Edition, *Evaluation of Linearity of Quantitative Measurement Procedures*, are shown in the following tables.

NOVEOS Specific IgE, F014, Soybean				
Dilution Series	Dilution Range (kU/L)	Slope (95% CI)	Intercept (95% CI)	R ²
1	0.07 to 1.43	1.05 (0.96 to 1.15)	0.00 (-0.02 to 0.02)	0.994
2	0.77 to 37.92	1.10 (1.02 to 1.18)	0.04 (-0.15 to 0.24)	0.996
3	21.27 to 124.26	0.98 (0.90 to 1.07)	-1.65 (-4.42 to 1.12)	0.994
All	0.07 to 124.26	1.02 (0.97 to 1.07)	0.01 (-0.01 to 0.02)	0.991

NOVEOS Specific IgE, F017, Hazelnut				
Dilution Series	Dilution Range (kU/L)	Slope (95% CI)	Intercept (95% CI)	R ²
1	0.08 to 3.56	0.97 (0.94 to 0.99)	-0.02 (-0.02 to -0.01)	0.999

2	0.67 to 39.98	1.00 (0.97 to 1.02)	-0.07 (-0.10 to -0.04)	1.000
3	20.19 to 111.87	1.05 (0.98 to 1.12)	-1.35 (-4.07 to 1.36)	0.997
All	0.08 to 111.87	0.99 (0.97 to 1.01)	-0.02 (-0.03 to -0.01)	0.998

NOVEOS Specific IgE, F352, Ara h 8 PR-10, Peanut				
Dilution Series	Dilution Range (kU/L)	Slope (95% CI)	Intercept (95% CI)	R ²
1	0.06 to 2.13	0.96 (0.90 to 1.01)	-0.01 (-0.04 to 0.02)	0.997
2	0.59 to 35.52	1.03 (0.98 to 1.07)	-0.01 (-0.05 to 0.02)	0.998
3	14.35 to 100.93	0.96 (0.81 to 1.10)	-3.23 (-6.93 to 0.47)	0.982
All	0.06 to 100.93	0.93 (0.88 to 0.97)	0.01 (-0.02 to 0.04)	0.991

NOVEOS Specific IgE, F423, Ara h 2, Peanut				
Dilution Series	Dilution Range (kU/L)	Slope (95% CI)	Intercept (95% CI)	R ²
1	0.09 to 3.42	0.98 (0.94 to 1.03)	0.00 (-0.01 to 0.01)	0.998
2	0.41 to 25.10	1.00 (0.93 to 1.07)	0.01 (-0.03 to 0.06)	0.997
3	15.76 to 99.09	1.05 (0.98 to 1.12)	-3.40 (-5.45 to -1.34)	0.997
All	0.09 to 99.09	0.97 (0.94 to 0.99)	0.00 (-0.01 to 0.01)	0.997

NOVEOS Specific IgE, F447, Ara h 6, Peanut				
Dilution Series	Dilution Range (kU/L)	Slope (95% CI)	Intercept (95% CI)	R ²
1	0.07 to 3.62	1.00 (0.98 to 1.02)	-0.02 (-0.02 to -0.01)	1.000
2	0.66 to 46.02	0.87 (0.79 to 0.96)	-0.03 (-0.16 to 0.10)	0.993
3	20.73 to 118.95	1.00 (0.94 to 1.05)	-0.30 (-2.13 to 1.54)	0.998
All	0.07 to 118.95	0.94 (0.91 to 0.98)	-0.01 (-0.02 to -0.00)	0.994

Endogenous Substance Interference

Interference testing by endogenous substances of NOVEOS sIgE allergens was carried out in accordance with CLSI guideline EP07, *Interference Testing in Clinical Chemistry – Third Edition*. The effect of the presence of elevated levels of human serum albumin, hemoglobin, triglyceride, conjugated bilirubin, and unconjugated bilirubin in serum samples was evaluated by testing three serum sample pools (one negative, one near the cut-off, and one positive) spiked with varying levels of each interferent. To mimic the dilution effect caused by the spiked interferent, the same amount of respective solvent was spiked into each of the sample pools and tested as control samples.

For NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) the samples were tested in replicates of seven in one assay run with one lot of Capture Reagent.

The % recovery for each sample spiked with the potential interfering substance was calculated

by comparing its result to that of the corresponding control sample. The substances listed in the table below show no significant interference at the indicated test concentrations for all allergens under evaluation.

Substance	Concentration
Hemoglobin	200 mg/dL
Conjugated Bilirubin	30 mg/dL
Unconjugated Bilirubin	20 mg/dL
Intralipid	3000 mg/dL
Human Serum Albumin	121 g/L

Interference testing with rheumatoid factor (RF) was previously performed for NOVEOS sIgE allergens and found no significant interference at 513 IU/mL. For RF interference testing, refer to cleared 510(k) submission K200825.

Exogenous Substance Interference

Interference testing with potentially interfering exogenous substances biotin, diphenhydramine, methylprednisolone, ranitidine, and omalizumab was previously performed for NOVEOS sIgE allergens and found no significant interference at the concentrations listed in the table below. Refer to previously cleared 510(k) submission K200825.

Substance	Concentration
Biotin	3500 ng/mL
Diphenhydramine	19.5 µmol/L
Methylprednisolone	1000 ng/mL
Ranitidine	19.1 µmol/L
Omalizumab	0.12 mg/mL

Cross-Reactivity

Cross-reactivity testing with other human immunoglobulins (IgA, IgD, IgG, and IgM) was previously performed for NOVEOS sIgE allergens that utilize the same universal anti-IgE conjugate reagent as those currently under evaluation and found no significant interference at physiological concentrations of IgA, IgG, IgM (14.86 mg/mL), and IgG (0.173 mg/mL). Refer to previously cleared 510(k) submission K200825.

Competitive Inhibition (Analytical Specificity)

Immunological specificity of NOVEOS sIgE allergens was demonstrated through competitive inhibition in accordance with CLSI I/LA20-3rd Edition, *Analytical Performance Characteristics, Quality Assurance, and Clinical Utility of Immunological Assays for Human Immunoglobulin E Antibodies of Defined Allergen Specificities*.

For each NOVEOS sIgE allergen, a positive sample was tested with specific IgE concentrations shown in the table below:

NOVEOS sIgE Allergen	Concentration (kU/L)
F014, Soybean	1.39
F017, Hazelnut	7.94
F352, Ara h 8 PR, Peanut	5.77
F423, Ara h 2, Peanut	6.48
F447, Ara h 6, Peanut	6.83

The allergen solution (inhibitor) was diluted 1:1 into the positive sample and subsequently serially diluted five times in two-fold increments. Each diluted sample was evaluated for dose-dependent inhibition in replicates of five using one lot of NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut).

Related and unrelated allergen inhibitors were tested for each NOVEOS sIgE allergen in a single-dose competitive inhibition study. The related and unrelated allergen inhibitors were tested at a concentration at least 10 times the final concentration that achieved >50% inhibition for the allergen under evaluation. The related and unrelated allergens used for each NOVEOS sIgE allergen are shown in the table below:

NOVEOS sIgE Allergen	Related Inhibitor	Unrelated Inhibitors
F014, Soybean	F018, Brazil Nut	• K082, Latex • M005, Candida albicans • W013, Cocklebur Pollen
F017, Hazelnut	F338, Sea Scallops	• D201, Blomia tropicalis • E070, Goose Feathers • I006, German Cockroach • I070, Fire Ant • M003, Aspergillus fumigatus • M012, Aureobasidium pullulans
F352, Ara h 8 PR, Peanut	F077, Bos d 5 β -lactoglobulin, Milk	• E221, Can f 3 Dog Serum Albumin, Dog • M218, Asp f 1, Aspergillus fumigatus • T215, Bet v 1 PR-10, Birch
F423, Ara h 2, Peanut	F427, Ara h 9 LTP, Peanut	• E221, Can f 3 Dog Serum Albumin, Dog • M218, Asp f 1, Aspergillus fumigatus • T215, Bet v 1 PR-10, Birch

NOVEOS sIgE Allergen	Related Inhibitor	Unrelated Inhibitors
F447, Ara h 6, Peanut	F076, Bos d 4 α -lactalbumin, Milk	- E221, Can f 3 Dog Serum Albumin, Dog - G215, Phl p 5b, Timothy Grass - M220, Asp f 3, Aspergillus fumigatus

Inhibitor concentrations used for testing of the NOVEOS sIgE allergens are shown in the table below:

NOVEOS sIgE Allergen	Dose-Dependent Inhibition		Single-Dose Inhibition	
	Highest Tested Inhibitor Conc. ($\mu\text{g/mL}$)	Final Conc. at >50% Inhibition ($\mu\text{g/mL}$)	Final Conc. of Related Inhibitor ($\mu\text{g/mL}$)	Final Conc. of Unrelated Inhibitors ($\mu\text{g/mL}$)
F014, Soybean	50	6.25	2180	975 - 1235
F017, Hazelnut	50	1.5625	250	250
F352, Ara h 8 PR, Peanut	50	6.25	3520	660 - 1970
F423, Ara h 2, Peanut	50	1.5625	31.25	31.25
F447, Ara h 6, Peanut	100	3.125	1460	1220 - 1970

Greater than 50% inhibition was achieved in the dose-dependent inhibition studies and no inhibition was observed for the related and unrelated inhibitors for all NOVEOS sIgE allergens. The inhibition studies indicate that the NOVEOS sIgE allergens contain their respective immunologically relevant allergens.

Detection Limit

Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantitation (LoQ) of NOVEOS sIgE allergens were estimated in accordance with CLSI guideline EP17-A2, *Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition*.

Limit of Blank

For F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) the study was done using two lots of capture reagent and one NOVEOS Immunoassay Analyzer. Four analyte-free human serum samples were tested in replicates of five per run, over three runs, with one run per day, for 60 replicates per lot. The value at the 95th percentile of the total measurements for each of the lots tested was estimated.

Limit of Detection

LoD for each assay was determined by testing multiple human serum samples with low IgE concentrations using two lots of capture reagents and one NOVEOS Immunoassay Analyzer. The LoD was calculated for each lot using parametric analysis.

The study protocol is summarized in the table below:

NOVEOS sIgE assay	No. of Samples	No. of Lots	No. of Analyzers	Testing Protocol
F014	5	2	1	5 samples x 5 replicates/run x 3 runs = 75/Lot
F017	6	2	1	4 samples x 5 replicates/run x 6 runs + 2 samples x 5 replicates/run x 3 runs = 150/Lot
F352	4	2	1	4 samples x 5 replicates/run x 3 runs = 60/Lot
F423	4	2	1	4 samples x 5 replicates/run x 3 runs = 60/Lot
F447	4	2	1	4 samples x 5 replicates/run x 3 runs = 60/Lot

Limit of Quantitation

LoQ was evaluated as a functional sensitivity-based approach with no bias component to LoQ. Functional sensitivity for NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) was determined using a set of four to six samples with low IgE concentrations and two lots of NOVEOS sIgE allergen. The samples were tested with five replicates, over three to six testing days resulting in a total of 60 to 150 replicates per lot. Data analysis was performed according to the precision profile method using within-lab precision results. The LoQ is defined as the mean value of the lowest sample or by calculating the mean dose at 20%CV which fulfills the specification for the total within-laboratory imprecision (<20%CV).

The claimed LoB, LoD, and LoQ are based on the highest value obtained from the lots tested and are summarized in the table below:

NOVEOS sIgE Allergen	LoB (kU/L)	LoD (kU/L)	LoQ (kU/L)
F014, Soybean	0.07	0.09	0.10
F017, Hazelnut	0.07	0.08	0.10
F352, Ara h 8 PR, Peanut	0.07	0.08	0.10
F423, Ara h 2, Peanut	0.07	0.09	0.10
F447, Ara h 6, Peanut	0.07	0.08	0.10

Reference Range

The expected value is negative (<0.35 kU/L) for a specific allergen in a non-atopic person. Each laboratory should establish its own expected value.

The expected value/reference range of NOVEOS sIgE assays for F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) in a normal population was verified in accordance with CLSI EP28-A3c, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory – 3rd Edition.

The 95% reference range was calculated by ordering the dose recoveries from 125 to 132 non-atopic samples in ascending order of concentration and identifying the dose recovery that fell at the

95th percentile rank. The 95% reference range for each allergen under evaluation was below the established NOVEOS sIgE cutoff of 0.35 kU/L.

Stability

Shelf-Life Stability

Both an ongoing real-time stability study and an accelerated stability study were performed for NOVEOS sIgE assays for F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) in accordance with CLSI EP25-Ed2 *Evaluation of Stability of In Vitro Medical Laboratory Test Reagents – Second Edition*. The accelerated stability study and ongoing real-time stability study were performed with two positive and one negative sample using three lots of NOVEOS sIgE allergen (Capture Reagent).

The accelerated stability data supports the manufacturer's claim of unopened shelf-life stability for the capture reagents as listed in the table below. Stability of common assay reagents (reagents except the Capture Reagent) has been established previously in prior submission K182479.

	Shelf-life Stability (2-8°C)
Specific IgE Capture Reagent F014*	36 months
Specific IgE Capture Reagent F017*	36 months
Specific IgE Capture Reagent F352*	36 months
Specific IgE Capture Reagent F423*	29 months
Specific IgE Capture Reagent F447*	26 months

*Based on accelerated stability data

Real-time stability studies of the NOVEOS sIgE allergens are on-going to further support the manufacturer's claim of unopened shelf-life stability when stored at 2-8°C per the manufacturer's instructions for use.

On-Board Stability (OBS)

Real-time OBS stability studies using one lot of NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) support the on-board stability claims for capture reagents as summarized in the table below. The real-time on-board stability study was performed with three samples, including two positive samples and one negative or low-level sample using one lot of NOVEOS allergen (Capture Reagent) stored on-board the instrument. OBS of common assay reagents (reagents except the Capture Reagent) has been established previously in prior submission K182479.

	On-board Stability (2-8°C)
Specific IgE Capture Reagent F014	28 days
Specific IgE Capture Reagent F017	28 days
Specific IgE Capture Reagent F352	28 days

	On-board Stability (2-8°C)
Specific IgE Capture Reagent F423	28 days
Specific IgE Capture Reagent F447	28 days

Open-Vial Stability (OVS)

Both an ongoing real-time stability study and an accelerated stability study were performed for the NOVEOS sIgE allergens F014 (Soybean), F017 (Hazelnut), F352 (Ara h 8 PR-10, Peanut), F423 (Ara h 2, Peanut), and F447 (Ara h 6, Peanut) in accordance with CLSI EP25-Ed2 *Evaluation of Stability of In Vitro Medical Laboratory Test Reagents – Second Edition*. OVS of common assay reagents (reagents except the Capture Reagent) has been established previously in prior submission K182479. The result supports that the allergen specific capture reagent is stable for 15 days once opened and stored at 2-8°C.

Real-time stability studies of the NOVEOS sIgE allergens are on-going to further support the manufacturer's claim of open-vial shelf-life stability when stored per the manufacturer's instructions for use.

Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.